NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 22 taking part
- Started
- 24 Jan 2022
- Primary completion
- Mar 2027
- Arms
- Cohort 1 (Low Dose)
- Results
- None posted
- 24 Jan 2022: Trial registered
- 24 Jan 2022: Trial started